Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback